25 May 2013
Keywords: intermune, completes, enrollment, ph, iii, actimmune, trial
Article | 24 April 2006
US drugmaker InterMune has completed patient enrollment in the INSPIRE trial, a pivotal Phase III clinical evaluation of Actimmune (interferon
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
24 May 2013
© 2013 thepharmaletter.com